Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.

CONCLUSIONS: Pegloticase treatment increased flares during the first 3 months of treatment in all groups when plasma urate was significantly lowered and was followed by a decline in months 4-6 in patients maintaining a low plasma urate. Flares associated with pegloticase treatment were associated with decreases and fluctuations in plasma urate levels. PMID: 33427618 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33427618?dopt=Abstract

Source: Clinical and Experimental Rheumatology - January 13, 2021 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research